Last reviewed · How we verify
NCT03180268
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Recruiting now
Phase 3
Last updated 14 January 2026
What this trial tests
Phase 3 trial testing Biospecimen Collection in Grade 2 Meningioma in 163 participants. Currently enrolling.
Timeline
12 September 2017
Primary endpoint
15 June 2027
15 June 2027
15 June 2027
Quick facts
| Lead sponsor | NRG Oncology |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 163 |
| Start date | 12 September 2017 |
| Primary completion | 15 June 2027 |
| Estimated completion | 15 June 2027 |
| Sites | 214 locations across Japan, Saudi Arabia, Canada, United States, India |
Drugs / interventions tested
- Biospecimen Collection — full drug profile →
- Clinical Observation
- Intensity-Modulated Radiation Therapy
- Laboratory Biomarker Analysis — full drug profile →
- Magnetic Resonance Imaging
- Proton Beam Radiation Therapy
- Quality-of-Life Assessment
Conditions studied
- Grade 2 Meningioma — all drugs for Grade 2 Meningioma →
- Intracranial Meningioma — all drugs for Intracranial Meningioma →
Sponsor
NRG Oncology — full company profile →
Who can join
18 and older, any sex, with Grade 2 Meningioma or Intracranial Meningioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
EANO guideline on the diagnosis and management of meningiomas.
Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, et al · · 2021 · cited 466× · PMID 34181733 · DOI 10.1093/neuonc/noab150 -
An overview of meningiomas.
Buerki RA, Horbinski CM, Kruser T, Horowitz PM, et al · · 2018 · cited 325× · PMID 30084265 · DOI 10.2217/fon-2018-0006 -
Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions.
Ogasawara C, Philbrick BD, Adamson DC. · · 2021 · cited 183× · PMID 33801089 · DOI 10.3390/biomedicines9030319 -
Advances in multidisciplinary therapy for meningiomas.
Brastianos PK, Galanis E, Butowski N, Chan JW, et al · · 2019 · cited 121× · PMID 30649489 · DOI 10.1093/neuonc/noy136 -
Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.
Wang JZ, Landry AP, Raleigh DR, Sahm F, et al · · 2024 · cited 100× · PMID 38695575 · DOI 10.1093/neuonc/noae082 -
Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas.
Maggio I, Franceschi E, Tosoni A, Nunno VD, et al · · 2021 · cited 100× · PMID 34015955 · DOI 10.2217/cns-2021-0003 -
Recent Advances in Meningioma Immunogenetics.
Al-Rashed M, Foshay K, Abedalthagafi M. · · 2019 · cited 39× · PMID 31970090 · DOI 10.3389/fonc.2019.01472 -
Predictors of early progression of surgically treated atypical meningiomas.
Budohoski KP, Clerkin J, Millward CP, O'Halloran PJ, et al · · 2018 · cited 36× · PMID 29961125 · DOI 10.1007/s00701-018-3593-x
Verify or expand the search:
- PubMed search for NCT03180268
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biospecimen Collection
Trials testing the same drug.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
Other recruiting trials for Grade 2 Meningioma
Currently open trials in the same condition.
- NCT04082520 — Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy · Phase 2 · recruiting
- NCT03604978 — Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Gr · Phase 1, PHASE2 · active not recruiting
Other NRG Oncology trials
Trials by the same sponsor.
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07452458 — Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, ID · Phase 3 · not yet recruiting
- NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
- NCT07097142 — Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemothera · Phase 3 · recruiting
- NCT06958328 — Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03180268 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NRG Oncology
- Last refreshed: 14 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03180268.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing